Vadadustat

Unassigned

New Medicines

Anaemia in chronic kidney disease in patients on dialysis - first-line

Information

New molecular entity
Otsuka
Akebia

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor. HIF transcription factors play a key role in activating expression of genes that control body defence mechanisms against low levels of oxygen. Taken once daily.
NICE reports UK prevalence of stage 3-5 CKD is between 4.9% and 5.6% (4,900 to 5,600 per 100,000 people) in unselected populations: many of these will have been near end of life and referral to renal services inappropriate [1,2]. Prevalence of anaemia in CKD (defined as a haemoglobin level less than 12 g/dL in men and postmenopausal women and less than 11 g/dL in premenopausal women) is about 12% [1].
Anaemia in chronic kidney disease in patients on dialysis - first-line
Oral

Anaemia in chronic kidney disease in patients not on dialysis

Information

Licence extension / variation
Otsuka
Akebia

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor. Hypoxia-inducible factors are transcription factors which play a key role in activating the expression of genes that control body defence mechanisms against low levels of oxygen. Taken once daily.
UK prevalence of stage 3-5 CKD is about 8.5% (8,500 per 100,000 people). Prevalence of anaemia in CKD (defined as a haemoglobin level less than 12 g/dL in men and postmenopausal women and less than 11 g/dL in premenopausal women) is about 12% [3].
Anaemia in chronic kidney disease in patients not on dialysis
Oral